Immunotherapies in Bladder Cancer Treatment: Expert Insights and Strategies

Get patient-specific treatment recommendations from experts with our Interactive Treatment Decision Support Tool. Review the data behind these recommendations in our CME/CE-certified virtual presentation with downloadable slides as well as short commentaries developed by the experts for the optimal use of immunotherapies for bladder cancer!
Matthew Galsky, MD
Matthew I. Milowsky, MD
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS
Jonathan E. Rosenberg, MD

ClinicalThought

Best practices for treating unresectable, locally advanced bladder cancer continue to evolve. Read my thoughts on tailoring treatment based on specific patient and disease characteristics in this setting.

Elizabeth R. Plimack, MD, MS Released: December 1, 2017

The evolution of immune checkpoint inhibitors for advanced bladder cancer may eventually replace chemotherapy. Read my thoughts on these new agents and how I use them in the clinic.

Matthew Galsky, MD Released: December 14, 2017

Patients with bladder cancer benefit most from a multidisciplinary approach tailored to their disease course. Read my thoughts on when and how urologists and oncologists should consider multidisciplinary patient management.

Daniel P. Petrylak, MD Released: May 22, 2018

Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.

Daniel P. Petrylak, MD Released: June 20, 2018

Are you aware of the recent FDA alert limiting first-line use of immune checkpoint inhibitors in patients with urothelial carcinoma? In this commentary, I explore the reasons for and the ramifications of this change.

Matthew I. Milowsky, MD Released: August 28, 2018

Are you aware of promising new options in clinical trials for your patients with bladder cancer who cannot receive cisplatin? Read my thoughts on the potential roles of neoadjuvant pembrolizumab and atezolizumab.

Matthew I. Milowsky, MD Released: September 10, 2018

Interactive Decision Support Tool

This Interactive Decision Support Tool will let you compare your choice of therapy for patients with advanced bladder cancer with expert recommendations from Matthew Galsky, MD; Matthew I. Milowsky, MD; Daniel P. Petrylak, MD; Elizabeth R. Plimack, MD, MS; and Jonathan E. Rosenberg, MD.

Matthew Galsky, MD Matthew I. Milowsky, MD Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Jonathan E. Rosenberg, MD Released: February 8, 2018

Interactive Virtual Presentation

In this virtual presentation, Elizabeth R. Plimack, MD, MS discusses the clinical rationale and data on the use of immune checkpoint inhibitors for patients with advanced bladder cancer. Afterwards, download the slides and use the treatment decision tool for your practice.

Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: April 30, 2018 Expiration: April 29, 2019

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.

Released: April 30, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?